Mesothelioma

News alerts, weekly reports and conference planners

Related cancers:

‹

Malignant Pleural Mesothelioma (33)

›

No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	cisplatin + raltitrexed Sensitive: A2 - Guideline cisplatin + raltitrexed Sensitive : A2	cisplatin + raltitrexed Sensitive: A2 - Guideline cisplatin + raltitrexed Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin + raltitrexed Sensitive: A2 - Guideline carboplatin + raltitrexed Sensitive : A2	carboplatin + raltitrexed Sensitive: A2 - Guideline carboplatin + raltitrexed Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
High 4-gene inflammatory score	Mesothelioma	High 4-gene inflammatory score	Mesothelioma	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
NF2 deletion	Malignant Pleural Mesothelioma	NF2 deletion	Malignant Pleural Mesothelioma	IK-930 Sensitive: B - Late Trials IK-930 Sensitive : B	IK-930 Sensitive: B - Late Trials IK-930 Sensitive : B
No biomarker	Mesothelioma	No biomarker	Mesothelioma	SynKIR-110 Sensitive: B - Late Trials SynKIR-110 Sensitive : B	SynKIR-110 Sensitive: B - Late Trials SynKIR-110 Sensitive : B
PD-L1 expression	Malignant Pleural Mesothelioma	PD-L1 expression	Malignant Pleural Mesothelioma	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1
BRCA1 mutation	Mesothelioma	BRCA1 mutation	Mesothelioma	rucaparib Sensitive: C1 - Off-label rucaparib Sensitive : C1	rucaparib Sensitive: C1 - Off-label rucaparib Sensitive : C1
BAP1 mutation	Mesothelioma	BAP1 mutation	Mesothelioma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
MSLN positive	Mesothelioma	MSLN positive	Mesothelioma	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
ROS1 positive	Mesothelioma	ROS1 positive	Mesothelioma	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2

Mesothelioma

Associations(88)

Associations
(88)